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Canavan disease (CD; MIM#271900), identified in 1931 by Canavan, is an inherited autosomal recessive progressive leukodystrophy with onset in early childhood or infancy. 
CD is more prevalent among individuals of Ashkenazi Jewish 
background, with an incidence of 1/6400 to 1/13,500 of the 
population, making 1 in every 40-58 Ashkenazi Jews a carrier [1]. 
However, the exact prevalence of the disease in the Indian 
population is not known. CD (spongy degeneration of the brain) 
is caused by a deficiency of aspartoacylase or N-acetylaspartate 
amino hydrolase. This enzyme catalyzes the hydrolysis of 
N-acetyl-l-aspartic acid (NAA) into aspartic acid and acetic acid. 
It presents with global developmental delay, poor head control, 
poor eye contact, hypotonia, seizures, and macrocephaly [2]. 
Most patients die within first few years of life. We report a case 
of CD who presented with the unusual features of normocephaly.
CASE REPORT
A 16-month-old male child born to a healthy couple presented 
with a history of increased head size since 6 months of age and 
delayed developmental milestones. On examination, the child had 
a weight of 5.5 kg (<−3 Z score), length 74 cm (between −2 and 
−3 Z score), and head circumference 48 cm (50–85th percentile 
as per the WHO charts). The baby’s birth weight was 2.2 kg and 
head circumference 34.5 cm (50th percentile as per the WHO 
charts). The child had no perception of light but could respond to 
sounds. The child was lying flaccid on the couch (hypotonia) with 
decreased muscle power and bulk. The deep tendon reflexes were 
within normal with positive Babinski sign. Rest of the systemic 
examination, as well as fundus examination, was normal.
The baby was a product of non-consanguineous marriage, 
as term normal vaginal delivery without any antenatal and 
perinatal complications. The elder sibling is developmentally 
normal, and there is no significant family history. The child 
developmentally did not achieve milestones as per age. Neck 
holding as well as bidextruous grasp were absent. The child could 
make cooing sounds only. Initially, we kept the possibility of 
leukodystrophy or storage disorders, and we planned blood and 
radiological investigations. The blood investigations revealed 
normal hemogram, liver function tests, and renal function tests. 
Metabolic workup including blood glucose, arterial blood gas, and 
urine for reducing substances, ketones, serum lactate, ammonia, 
and tandem mass spectrometry were noncontributory. The 
infant was further evaluated with a magnetic resonance imaging 
(MRI) brain performed on a 1.5 T MR scanner (Philips Medical 
Systems). MRI brain revealed diffuse bilateral white matter 
T2/fluid-attenuated inversion recovery hyperintensities and T1 
hypointensity involving bilateral subcortical U fibers, centrum 
semiovale, corona radiate, globus pallidus, and periventricular 
white matter with no contrast enhancement. Proton magnetic 
resonance spectroscopy (H-MRS) at echo time - 23 ms, repetition 
time - 2000 ms showed high NAA and mI peak with NAA: 
Creatinine ratio of 7.27:1 (normal: 2.09±0.45) suggestive of 
CD. It was confirmed by a urinary organic acid profile by gas 
chromatography–mass spectrometry, which showed elevated 
urinary NAA levels to be 520 µmol/mmol creatinine (normal: 
<10 µmol/mmol creatinine).
DISCUSSION
CD is a globally occurring but rare early-onset human spongiform 
leukodystrophy associated with inborn genetic errors affecting the 
activity of aspartoacylase (ASPA), the enzyme highly expressed 
in oligodendrocytes that hydrolyzes NAA to acetate and 
aspartate. While the role of NAA in neuronal development is still 
unclear, its accumulation in the brain in CD is postulated to cause 
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myelin damage and progressive spongiform degeneration [3]. 
In Ashkenazi Jews, the risk for affected children is 1:6400 to 
1:13,500 [1]. However, the exact prevalence of the disease in the 
Indian population is not known. Patients usually present within 
the first 6 months of life with hypotonia, poor head control, loss 
of visual fixation, macrocephaly, and head lag. CD generally 
follows a rapidly progressive clinical course and results in death 
by the 3rd year of life [4].
One of the hypotheses suggested for the pathophysiology 
of CD is that excessive NAA accumulated in the brain due to 
the ASPA gene mutation acts as a water pump and produces 
astrocytic edema, intramyelinic vacuole formation, and spongy 
degeneration of the brain parenchyma which manifests as brain 
swelling. Macrocephaly results from a combination of brain 
swelling and abnormal skull growth in CD [5]. Our patient also 
presented at 6 months of age with hypotonia, loss of visual fixation 
and head lag and normocephaly. Most cases of CD reported in 
literature presented with macrocephaly. There are few reported 
cases of CD with normocephaly. These cases of normocephalic 
CD had a milder clinical course, and their cerebral and urinary 
NAA levels were less than those found in classic cases [6,7]. This 
could probably be due to a variable expression of the ASPA gene 
that led to a severe clinical course followed by a rapid neuronal 
loss.
Advanced stage of CD is associated with the loss of white 
matter and neurons [8]. This probably caused decreased NAA 
production and coupled with reduced ASPA enzyme activity, 
resulted in a moderate increase in NAA levels that was reflected 
on MRS. The relative decrease in NAA levels and neuronal loss 
could have prevented swelling of the brain. This in turn probably 
prevented excessive skull growth and resulted in normocephaly 
at the time of presentation. In the present case, the clinical course 
was similar to that of the classic CD. However,  The cerebral NAA 
levels as demonstrated by MRS showed a moderate elevation of 
NAA, and the urinary NAA levels showed the levels to be 520 
µmol/mmol creatinine, which is much less compared to the levels 
seen in classic cases of CD. These findings are consistent with 
the reports of Velinov et al., who ascribed the normocephaly, to 
the particular mutation seen in their cases [7]. In our patients, we 
could not do genetic analysis due to financial constraints. These 
findings are also consistent with the findings of Janson et al. [6]. 
Both triheptanoin as well as gene therapy are promising treatment 
approaches for CD, but they are still in their infancy to establish 
an approved therapy for patients with CD.
CONCLUSION
CD is a rare neurological disorder with an overall small number 
of patients. This case illustrates the fact that the presence of 
normocephaly should not be used in isolation to rule out the 
possibility of CD.
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